Профиль

There’s a ton of uncertainty about what the future will bring, but IMO the case for giving ambitiously today looks unusually strong. Let’s get to work!

That’s nearly as much as we’ve given based on GiveWell's recs over the last decade+; we think that funding to date has saved ~100,000 lives.

I’m really excited about this: we’re increasing our support for GiveWell recs this year from $175M to $1B to help pave the way for an expected surge in funding from others. coefficientgiving.org/research/in...

New CBO paper: every $1 of federal R&D returns ~$3–$4 of GDP in present value over 30 years www.nber.org/papers/w35472

I've spent my career working on vaccines, and until I joined Coefficient Giving, I'd never heard Strep A mentioned as a global health priority. The more I looked, the harder it was to understand why a disease killing 630,000+ people a year was so neglected.

Cool to see this! content.govdelivery.com/accounts/US...

Links to listen - Spotify: open.spotify.com/episode/35i... Apple Podcasts: podcasts.apple.com/us/podcast/...

Thanks @alterigoe.bsky.social for having me on @devex.com's new Theory of Change podcast. We talked about how we pick problems at Coefficient Giving, why Strep A stands out as a unique opportunity, and the challenge of making big bets across long time horizons: youtu.be/0SLzoKxQqHg

Looks like Eric Adams really delivered on housing production with City of Yes newyorkyimby.com/2026/05/new-...

And I'm thrilled to be betting on Katharine's vision here! As a grad student, she co-invented the R21 malaria vaccine that's now reaching millions of kids. I'm hoping to see hundreds of millions of future Strep A vaccine doses with her fingerprints on them.

Our goal is to double the number of Strep A vaccine candidates in clinical trials and have at least one ready for Phase 3 trials by the end of 2030.

Grateful to our partners Adam and Abigail Winkel, Good Ventures, Lucy Southworth, The Patchwork Collective, and a few anon donors for getting us to >$140M at launch. We're continuing to actively fundraise and think we could effectively spend >$200M over the next few years.

→ A huge problem: ~1% of total annual deaths worldwide (>600k) → Super neglected: ~$14M/yr of R&D globally before this, ~50x less than malaria which has similar mortality → Newly tractable: new human challenge models and earlier diagnostics should speed the path to an approved vaccine

I'm really excited about the >$140 million Strep A Vaccine Fund we're launching today. I think the basic case here is a great recipe for impact ↓ bsky.app/profile/kat...

Great to see GiveWell CEO Elie Hassenfeld on the TIME100 Philanthropy list, well chosen! time.com/collection/...

Full article: calmatters.org/politics/20...

Pretty cool: @cayimby.bsky.social declined to endorse anyone for California governor because all the top candidates have strong housing plans

Full post (and more on the nature of our grantmaking work) from my colleague Luke Muehlhauser here: multipliercg.substack.com/p/ai-safety...

We're hiring 10+ grantmakers and senior generalists across our GCR teams. Most of our capital is bottlenecked on a tiny number of people working to identify, vet, and generate strong funding opportunities. Apply here by May 24: jobs.ashbyhq.com/coefficient...

I'm hopeful that the End Kidney Deaths Act — which would create a pilot program offering a $50K tax credit to people who donate a kidney to a stranger — will move forward this Congress. If you want to help, consider signing the petition at endkidneydeathsact.org